
Simbec-Orion Expands Immunoassay Capability
In line with our continuing investment in technology, we have recently expanded our immunoassay capability with the addition of a ...Read more >
In line with our continuing investment in technology, we have recently expanded our immunoassay capability with the addition of a ...Read more >
Warsaw, 3rd July 2023 Molecure has signed an agreement to conduct a Phase II clinical trial for its lead molecule ...Read more >
We are delighted to share that Simon Jennings as joined Simbec-Orion as Vice President, Data Sciences. Simon has over 35 ...Read more >
Le groupe Simbec-Orion a reçu l’accréditation pour la taxe Recherche & Développement ‹‹CIR – Crédit d’Impôt Recherche›› qui donne droit ...Read more >
How confident are you in your route to the clinic? There are multiple hurdles to be navigated, many of which ...Read more >
Outsourcing is common practice in clinical trials; as the global clinical research market becomes ever more competitive, small to mid-size ...Read more >
The development of bioanalytical methods and subsequent quantification of analytes in a range of biological matrices is fundamental to the ...Read more >
You are coming close to having completed your nonclinical studies and you are beginning to think about your next steps. ...Read more >
The world of medical research and development is constantly advancing, and clinical trials play a crucial role in bringing new ...Read more >
Being first to market with an innovator drug remains the ultimate goal for all, and most organisations are constantly reviewing ...Read more >
February 27, 2023 Simbec-Orion are pleased to share that dosing with MDI-26478, Cardiff University’s Medicines Discovery Institute’s (MDI) potential novel ...Read more >
The successful delivery of another Phase I clinical trial by the team at Simbec-Orion has resulted in the achievement of ...Read more >